Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Evasion of forkhead box O (FOXO) transcription factor-mediated growth suppression is crucial for cancer development.
• FOXO gene alterations are infrequent in human cancers, suggesting post-translational mechanisms for their elimination.
• Casein Kinase 1 alpha (CK1α) regulates FOXO3A stability in an oncogenic RAS-specific manner, but its effect on other FOXO members is unknown.

Purpose of the Study:

• To investigate if CK1α destabilizes FOXO4 in RAS-mutant cells.
• To elucidate the role of oncogenic RAS signaling in FOXO4 degradation.
• To evaluate the therapeutic potential of targeting CK1α and the proteasome in RAS-mutant cancers.

Main Methods:

• Phosphorylation site mapping of FOXO4.
• Analysis of PI3K/AKT signaling pathway activation.
• Assessment of proteasome subunit expression and activity.
• Cell viability assays and apoptosis induction studies following dual inhibition of CK1α and proteasome.

Main Results:

• CK1α destabilizes FOXO4 in RAS-mutant cells via phosphorylation at serines 265/268.
• Oncogenic RAS signaling, partly through PI3K/AKT, primes FOXO4 for CK1α-dependent degradation.
• Mutant RAS upregulates proteasome activity to degrade nuclear FOXO4.
• Dual inhibition of CK1α and proteasome synergistically reduces RAS-mutant cancer cell growth by blocking FOXO4 degradation and inducing apoptosis.

Conclusions:

• CK1α and proteasome-mediated degradation, not nuclear export, eliminates FOXO4 tumor suppressors in RAS-mutant cancers.
• Oncogenic RAS utilizes post-translational mechanisms to degrade FOXO proteins, thereby promoting cancer.
• Targeting CK1α and the proteasome simultaneously presents a promising therapeutic strategy for RAS-mutant cancers.